Abata Therapeutics has received an undisclosed amount as an equity investment from Bristol Myers Squibb.
The funds are intended to support the clinical development of Abata's Treg cell therapy products, with the company planning to start clinical trials for its ABA-101 therapy for progressive multiple sclerosis (MS).
Abata Therapeutics focuses on developing targeted therapies for autoimmune and inflammatory diseases using regulatory Treg technology. The company’s lead programs include treatments for progressive MS, type 1 diabetes, and inclusion body myositis. Its technology leverages Tregs to infiltrate, disrupt, and suppress inflammation at the disease site, offering targeted delivery.
Analyst QuickTake: The ABA-101 therapy for MS received the Investigational New Drug (IND) designation from the US FDA in July 2024 . It is a patient-derived T cell receptor (TCR)-Treg cell therapy created specifically for patients with progressive MS.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.